Vitality Awaiting CBD Drug Patents to Treat MS, Addiction, Stroke, Schizophrenia
Los Angeles-based cannabis biotech Vitality Biopharma, Inc. (OTCQB: VBIO) filed national patent applications in the US and Canada in October for cannabidiol (CBD) compounds effective in neural repair using remyelination, and is still waiting to hear results.
Cannabidiol (CBD), a non-intoxicating cannabinoid the FDA already approved to treat epilepsy, is also known to relieve pain through modulation of the TRPV1 receptor. As a result, Vitality made broad patent claims covering use of CBD and other TRPV1 agonists for myelin repair.
The patent rights are based on work performed by the Myelin Repair Foundation (MRF), which assigned these rights to Vitality in 2016. The results were published in BMC Neuroscience. Researchers discovered several drugs useful in effecting remyelination, a form of nervous system regeneration critical to restoring lost function from multiple sclerosis. Emerging research also points to a role in addiction, stroke, and schizophrenia.
While many maladies have underlying health conditions, it’s important to maintain a healthy immune system with diet and exercise to help prolong your body’s expiration date. Read more about how you can use supplements for both pre-workout and post-workout to help maintain a healthy immune system.
Vitality Biopharma is working with cannabinoids to discover treatments for neurological and inflammatory disorders. For more information, visit: www.vitality.bio or follow it on Facebook, Twitter and LinkedIn.
Want to learn more? Sign up for Cannin Free Access and subscribe to the Cannin Chronicle. We’ll keep you informed on all things cannabis and even help you determine which cannabis companies have the highest growth potential.
Source Vitality press release
Vitality Awaiting CBD Drug Patents to Treat MS, Addiction, Stroke, Schizophrenia
About Cannin: Your Marijuana Investment Experts
Cannin is your trusted resource for information about marijuana and hemp stock investment opportunities. Our global team of experts evaluates all emerging marijuana and hemp stock investing opportunities. We aggregate hundreds of hours of research and provide tips on the best marijuana and hemp stock investments for 2020. We provide the latest marijuana investment and hemp investment news and analysis.
Use Cannin as your resource for breaking cannabis and hemp investing news, featured cannabis and hemp company analysis, comprehensive cannabis and hemp stock reports, or get your free trial now and use our Smart Stock Algorithm to take the guesswork out of profiting from the cannabis industry. Is it too late to invest in marijuana or hemp stocks? No! This is the perfect time to invest.
Market analysts expect the marijuana and hemp industry will have an annual value exceeding $75 Billion in the next decade. The time to invest in marijuana and hemp stocks is now. Are you looking to buy stock in hemp companies or marijuana companies for 2020? Interested in emerging penny hemp stock companies? Looking for the best Canadian marijuana stocks to invest in? We can help.
Predict price movements of marijuana and hemp stocks several hours in advance with our proprietary algorithmic stock trading software.
Profit from the best marijuana stocks – we’ll show you how at cannin.com
